Trial Profile
Developing Neuronal KCNQ Channel Modulators for Mood Disorders
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Retigabine (Primary)
- Indications Major depressive disorder
- Focus Proof of concept; Therapeutic Use
- 03 Mar 2021 Primary endpoint (Change in the cortico-striatal circuit response) has not been met, as per Results published in the American Journal of Psychiatry
- 03 Mar 2021 Results published in the American Journal of Psychiatry
- 06 Sep 2019 Status changed from recruiting to completed.